PRIMARY

THE DISEASERaising Incidence: 6000 nc/yr , 1500 dead/yr Younger patients !!

7%

14%

67%

40% 33%

60%

86%93%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

< 0.76 0.76-1.69 1.70-3.60 > 3.60

Thickness-mm

Out

com

e

DOD

alive

Until Recently ……

PrognosisMETASTATIC

IMPROVED Prevention and Early Diagnosis reduced Mortality Rate with Screening Programs

( J. Invest. Dermatol 132:1311.2012)

A PREVENTABLE DISEASE !!!

High Cure Rates

B

D E F

C

Fibroblasts

Loss of keratinocytes controlAngiogenesis

MotilityInvasion

Growth

ECM ECM

Molecular Characterization of Tumor Progression

The Biology

RGPVGP

Translational Relevance

Small molecules target therapy

S L N Imaging

Immuno-therapyAgonistic and Antagonist Recepotrs

Gene Array

Table 3. Antigenic Phenotype of ABCG+ IGR37 melanoma xenograft

Differentiation Ags Progression Ags Cancer testis AgsHMW-MAA positive CD9 positive NY-ESO-1 negativeHBM-45 positive c-met positive MAGE-A positiveMelan-A positive HER-3 positiveET-Br positive Tenascin positiveET-1 negative

Plos One Dec,2010

“Stem” Cells

Table 3. Antigenic Phenotype of ABCG+ IGR37 melanoma xenograft

Differentiation Antigens Progression antigens Cancer testis antigensHMW-MAA positive CD9 positive NY-ESO-1 negativeHBM-45 positive c-met positive MAGE-A positiveMelan-A positive HER-3 positiveET-Br positive Tenascin positiveET-1 negative

Plos One Dec,2010

THE DISEASEIncidence: 6000 nc/yr , 1500 dead/yr

7%

14%

67%

40% 33%

60%

86%93%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

< 0.76 0.76-1.69 1.70-3.60 > 3.60

Thickness-mmO

utco

me

DOD

alive

Resistant……..

to available therapies

Prognosis

IMPROVED

Prevention and Early Diagnosis

A PREVENTABLE DISEASE !!!

IMPROVED

Prevention and Early Diagnosis

THE DISEASEIncidence: 6000 nc/yr , 1500 dead/yr

A PREVENTABLE DISEASE !!!